실시간
FierceBiotechCompass, Usona score FDA national priority vouchers amid Trump administration’s psychedelic pushBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 23, 2026FierceBiotechChutes & Ladders—Helus shuffles out CEO after two months, adds experience to science boardFierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?BioWorldIn the clinic for April 24, 2026BioWorldOther news to note for April 24, 2026BioWorldRegulatory actions for April 24, 2026PLoS BiologyA cortico-subthalamic circuit rapidly engages and releases inhibition of specific movements depending on the environmental contextPLoS BiologyA mother’s gift: Provisioning of plastid-derived structures into eggs promotes invertebrate development and dispersalPLoS BiologyEmergent spatial structure in the gut microbiota is driven by bacterial growth and gut contractionsBioWorldSichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld 2026년 4월 21일

Delta-Fly eyes NDA path despite AML phase III miss

Delta-Fly eyes NDA path despite AML phase III miss

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.